levofloxacin has been researched along with sertraline in 12 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (sertraline) | Trials (sertraline) | Recent Studies (post-2010) (sertraline) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,480 | 1,028 | 1,329 |
| Protein | Taxonomy | levofloxacin (IC50) | sertraline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.083 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.9848 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.7675 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 2.6309 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.8 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.5073 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.2888 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.4 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.2882 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 8.3173 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1814 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.477 | |
| D | Rattus norvegicus (Norway rat) | 0.26 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.8783 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.825 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.7409 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.083 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.8 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0016 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.1743 | |
| Melanocortin receptor 5 | Homo sapiens (human) | 4.598 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.655 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.3935 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.2175 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.3173 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 8.3173 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0697 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.26 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brain, RA; Hanson, ML; Johnson, DJ; Lam, MW; Mabury, SA; Richards, SM; Sanderson, H; Sibley, PK; Solomon, KR; Young, C | 1 |
| Nolan, KA; Oshman, RG; Phelps, RG; Pulitzer, MP | 1 |
1 review(s) available for levofloxacin and sertraline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for levofloxacin and sertraline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum.
Topics: Acetaminophen; Analysis of Variance; Atorvastatin; Biological Assay; Biomass; Caffeine; Carbamazepine; Complex Mixtures; Dose-Response Relationship, Drug; Heptanoic Acids; Heterocyclic Compounds; Levofloxacin; Magnoliopsida; Ofloxacin; Pharmaceutical Solutions; Pyrroles; Sertraline; Sulfamethoxazole; Toxicity Tests; Trimethoprim; Water Pollutants, Chemical | 2004 |
CD30+ lymphomatoid drug reactions.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amines; Amlodipine; Anti-Bacterial Agents; Anticonvulsants; Biomarkers; Biopsy; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Drug Eruptions; Erythema; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Immunohistochemistry; Ki-1 Antigen; Levofloxacin; Lymphocytes; Lymphoproliferative Disorders; Male; Metoprolol; Middle Aged; Ofloxacin; Predictive Value of Tests; Pseudolymphoma; Selective Serotonin Reuptake Inhibitors; Sertraline; Skin | 2013 |